Concepedia

Janelle Sabo

JS

7

Publications

2.8K

Citations

7

H-Index

2000

Active since

Affiliations

Eli Lilly (United States)(Current)

Cedars-Sinai Medical Center

University of North Carolina at Chapel Hill

University of Missouri–Kansas City

Family Health International 360

Janelle Sabo is an author at Eli Lilly (United States) specializing in anti-infective agents, drug resistance, and antimicrobial pharmacokinetics.

Top concepts

Publications per year

2000–2021

7

Publications

7

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen, Ajay Nirula, Barry N. Heller et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

Robert Gottlieb, Ajay Nirula, Peter Chen et al. · JAMA · 2021 · 931 citations · Full text

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen, Ajay Nirula, Mark J. Mulligan et al. · JAMA · 2021 · 208 citations · Full text

Voriconazole: A New Triazole Antifungal

Janelle Sabo, Susan M. Abdel‐Rahman · Annals of Pharmacotherapy · 2000 · 171 citations

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load

Michael Dougan, Masoud Azizad, Bharat Mocherla et al. · Clinical Infectious Diseases · 2021 · 68 citations · Full text

Rows per page

1–5 of 7